查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2014746

醫院感染治療市場：2026-2032年全球市場預測（依藥物類別、給藥途徑、應用、最終用戶及通路分類）

Hospital Infection Therapeutics Market by Drug Class, Route Of Administration, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，醫院感染治療市場價值將達到 68.9 億美元，到 2026 年將成長至 74.4 億美元，到 2032 年將達到 122.8 億美元，複合年成長率為 8.59%。

主要市場統計數據
基準年 2025 68.9億美元
預計年份：2026年 74.4億美元
預測年份 2032 122.8億美元
複合年成長率 (%) 8.59%

簡要介紹醫院感染治療的臨床、商業性和營運背景，強調需要採取綜合策略應對措施。

醫院感染疾病治療仍然是保障病人安全和醫療品質的核心支柱，它融合了臨床實務、供應鏈韌性和法律規範。近年來，採購、抗菌藥物的合理使用以及分銷管道等方面的薄弱環節暴露無遺，這要求我們採取更全面的觀點，將臨床優先事項與商業性現實相結合。本執行摘要概述了醫院領導、製造商和經銷商在製定策略和營運應對措施時需要考慮的關鍵主題。

分析臨床、製造和分銷領域的變革融合，這些變革正在重新定義以醫院為基礎的感染疾病治療和相關人員的合作。

醫院感染疾病治療領域正經歷著變革性的轉變，這主要由幾個並行的趨勢所驅動，這些趨勢正在重塑臨床決策和供應鏈結構。快速診斷和就地檢驗的進步使得更有針對性的治療方法成為可能，並推動著治療模式從廣泛的經驗性治療逐步轉向精準的標靶治療。同時，合理用藥方案與採購獎勵的關聯日益緊密，形成了一個反饋循環，在這個循環中，臨床療效和降低抗藥性的需求都會影響藥物的選擇決策。

對新的關稅趨勢將如何影響醫院治療領域的供應鏈脆弱性、採購複雜性和臨床替代策略進行全面分析。

關稅政策的變化會對整個醫院感染疾病治療市場產生重大影響，即使它們不會直接影響成品藥。活性成分、無菌組件、一次性醫療設備和包裝的關稅增加可能會提高進口後成本，並擠壓製造商和經銷商的利潤空間。因此，採購團隊在成本預測和合約談判方面將面臨更大的複雜性，而製造商可能會重新評估其供應商所在地，並考慮將關鍵生產環節遷回或轉移到鄰國附近。

詳細的細分分析揭示了藥物類別、給藥途徑、最終用戶、分銷管道和臨床應用如何綜合決定籌資策略和臨床策略。

要了解市場，需要從藥物類別、給藥途徑、最終用戶、分銷管道和應用等多個維度進行詳細觀點。整體情況包括抗生素、抗真菌藥物、消毒劑和抗病毒藥物。抗生素包括碳青黴烯類、頭孢菌素類、氟喹諾酮類、Fluoroquinolones和青黴素類等亞類；抗真菌藥物包括Azole、棘白菌素類和Polyenes；消毒劑包括酒精類製劑、氯己定和碘伏；抗病毒藥包括用於治療乙型肝炎、丙型肝炎、愛滋病和流感的藥物。每類藥物都有其獨特的臨床應用模式、合理用藥注意事項、生產要求和監管途徑，這些因素處方集。

區域策略分析解釋了美洲、歐洲、中東和非洲以及亞太地區的差異如何影響醫院的監管、製造和分銷重點。

區域趨勢對美洲、歐洲、中東和非洲以及亞太地區的治療藥物的可近性、監管預期和商業策略有顯著影響。在美洲，醫院系統的整合以及對基於價值的採購的重視，推動了對具有明確臨床和經濟效益的治療方法的需求。同時，分銷網路通常傾向於集中式聯合採購和一體化供應合約。相較之下，歐洲、中東和非洲的法規環境和採購框架各不相同，國家法規、報銷機制和區域製造地都會影響藥物的可及性和定價。強調合理使用抗菌藥物和預防感染的政策舉措在不同地區也存在顯著差異。

一份深入的公司分析報告，探討了創新者、專家、非專利生產商和分銷合作夥伴如何塑造醫院感染疾病治療的可及性、韌性和臨床支持。

競爭格局包括跨國製藥創新企業、專注於新型抗菌和抗病毒藥物的生物技術公司、學名藥生產商以及為醫院提供藥物的經銷商。擁有廣泛感染疾病產品組合的行業領導者通常會將抗病毒和抗菌藥物的研發與大規模生產能力和成熟的分銷網路相結合，以便在臨床療效得到證實後迅速推廣新治療方法。專業生物技術公司和大學衍生企業往往是下一代藥物和輔助性治療的來源，而學名藥生產商和契約製造在維持經濟高效的藥物供應和生產穩定性方面發揮著至關重要的作用。

為臨床、採購、製造和商業領域的領導者提供以行動為導向、優先考慮的建議，以增強供應彈性、正確使用和市場靈活性。

產業領導者應優先考慮跨職能管治，將臨床、採購、監管和商業團隊聚集在一起，在處方集決策、合約結構和緊急時應對計畫方面達成一致。加強供應商合格流程並實現活性成分和無菌成分來源多元化，可以降低受地理和政策因素影響的風險。同時，增加對診斷支持和管理分析的投入，有助於將治療方案轉向標靶治療，從而維持臨床療效並減緩抗藥性的出現。

本文檔詳細介紹了用於為管理層提供見解的高度透明的調查方法，包括一手研究、供應鏈映射、定性檢驗和情境分析。

本研究途徑結合了對臨床負責人、採購專家和行業高管的訪談，以及對監管文件、品質指南和公開行業報告的二次分析。定性訪談提供了有關營運限制和推廣障礙的背景信息，而供應鏈圖譜則確定了活性成分採購、無菌組件和配送流程中的關鍵環節。分析架構整合了臨床路徑圖譜、供應商風險評估和商業通路評估，從而得出全面的見解。

策略重點的果斷整合，強調臨床管理、供應多樣化和跨部門實施，以確保患者照護和醫療服務。

醫院感染疾病治療面臨臨床緊迫性和運作複雜性並存的雙重挑戰。確保病患安全和獲得有效治療需要採取綜合性方法，涵蓋臨床管理、採購政策、生產策略和分銷設計。貿易政策的近期變化、臨床診斷技術的進步以及分銷模式的改變，進一步凸顯了跨部門合作和緊急時應對計畫的必要性。積極拓展供應來源、投資於基於診斷的處方策略並建立靈活的商業合約的機構，將更有利於維持醫療服務的連續性並支持最佳的臨床療效。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：醫院感染治療市場：依藥物類別分類

  • 抗生素
    • 碳青黴烯類
    • 頭孢菌素
    • Fluoroquinolones
    • 大環內酯類
    • 青黴素
  • 抗真菌藥物
    • Azole
    • 棘白菌素
    • Polyenes
  • 消毒劑
    • 酒精類
    • 氯己定
    • 碘類藥物
  • 抗病毒藥物
    • 抗B型肝炎藥物
    • 抗HCV
    • 抗愛滋病毒
    • 抗流感

第9章：院內感染治療藥物市場：依給藥途徑分類

  • 吸入
  • 口服
  • 腸外
    • 肌肉內部
    • 靜脈
    • 皮下
  • 外用

第10章：醫院感染治療市場：依應用領域分類

  • 寬慰
  • 預防
    • 術後
    • 術前
  • 治療
    • 經驗
    • 標靶治療

第11章：醫院感染治療市場：依最終使用者分類

  • 門診手術中心
  • 診所
  • 家庭醫療保健
  • 醫院

第12章：醫院感染治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房
  • 批發商

第13章：院內感染治療藥物市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：醫院感染治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：醫院感染治療藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國醫院感染治療市場

第17章：中國醫院感染治療藥物市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • AstraZeneca plc
  • Aurobindo Pharma Ltd.
  • Basilea Pharmaceutica Ltd.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Iterum Therapeutics plc
  • Johnson & Johnson Services, Inc.
  • Melinta Therapeutics, LLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Shionogi & Co., Ltd.
  • Spero Therapeutics, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Theravance Biopharma, Inc.
  • Viatris Inc.
Product Code: MRR-43127F7278A5

The Hospital Infection Therapeutics Market was valued at USD 6.89 billion in 2025 and is projected to grow to USD 7.44 billion in 2026, with a CAGR of 8.59%, reaching USD 12.28 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.89 billion
Estimated Year [2026] USD 7.44 billion
Forecast Year [2032] USD 12.28 billion
CAGR (%) 8.59%

Concise introduction framing the clinical, commercial, and operational context for hospital infection therapeutics while highlighting the need for integrated strategic responses

Hospital infection therapeutics remain a central pillar of patient safety and quality of care, intersecting clinical practice, supply chain resilience, and regulatory oversight. Recent years have exposed vulnerabilities across procurement, antimicrobial stewardship, and distribution channels, requiring a more integrated perspective that aligns clinical priorities with commercial realities. This executive summary synthesizes critical themes that hospital leaders, manufacturers, and distributors must consider when shaping strategy and operational responses.

The landscape is characterized by a convergence of factors: evolving pathogen profiles and resistance patterns; the maturation of novel antiviral and antifungal agents; the sustained importance of antiseptic protocols; and mounting pressure on procurement teams to ensure uninterrupted access to key therapies. Consequently, stakeholders must balance acute operational needs with medium- to long-term investments in pipeline development, stewardship programs, and alternative sourcing strategies. This introduction sets the stage for a structured examination of transformative shifts, tariff-related headwinds, segmentation intelligence, regional differences, competitive dynamics, recommended actions, and research rigor that underpins the report.

Analysis of the converging clinical, manufacturing, and distribution transformations that are redefining hospital infection therapeutics and stakeholder collaboration

The hospital infection therapeutics sector is undergoing transformative shifts driven by several concurrent trends that are reshaping clinical decision-making and supply chain structures. Advances in rapid diagnostics and point-of-care testing are enabling more targeted therapy selection, which is prompting a gradual pivot from broad empirical regimens to precision-targeted approaches. At the same time, stewardship programs are increasingly intertwined with procurement incentives, creating a feedback loop in which formulary decisions are informed by both clinical efficacy and resistance mitigation imperatives.

Parallel to clinical innovation, distribution models are evolving. Increased digitalization of procurement, growth in online pharmacy fulfillment, and pressure on wholesaler margins are motivating hospitals and health systems to reassess direct purchasing, consignment models, and strategic inventory buffers. Manufacturing trends are also significant; a shift toward specialized manufacturing for parenteral formulations and sterile injectables, combined with increasing scrutiny of quality and regulatory compliance, means supply continuity depends on robust supplier qualification and geographic diversification of critical inputs. These shifts collectively demand that clinical leaders work more closely with supply chain and commercial teams to harmonize therapeutic strategy with sourcing reliability and cost management.

Comprehensive analysis of how new tariff dynamics will compound supply chain fragility, procurement complexity, and clinical substitution strategies in hospital therapeutics

Tariff policy changes exert a powerful influence across hospital infection therapeutics even when they do not directly affect finished medicines. Increased duties on active pharmaceutical ingredients, sterile componentry, single-use devices, and packaging can raise landed costs and compress margins for manufacturers and distributors. As a consequence, procurement teams face heightened complexity in cost forecasting and contract negotiation, while manufacturers reassess supplier footprints and consider reshoring or nearshoring of critical production stages.

The tariff environment also exacerbates existing supply chain fragilities for parenteral and sterile products, where specialized equipment and validated production sites limit rapid capacity scaling. Hospitals that rely on just-in-time inventory models may experience greater exposure to intermittent shortages, prompting a strategic recalibration toward safety stock, multi-sourcing, and longer contract terms with clause structures that address force majeure and cost pass-through. In parallel, increased import costs can incentivize local manufacturing investment, but such transitions require capital, regulatory relocation, and time, meaning near-term impacts will mainly be managed through contracting strategies and inventory policies.

Clinically, tariff-related shifts can alter the availability and procurement prioritization of certain drug classes. Facilities may prioritize therapeutically equivalent generics or alternative antiseptic formulations to maintain continuity of care. Consequently, antimicrobial stewardship teams must work with procurement and formulary committees to update treatment pathways and ensure substitutions maintain clinical effectiveness while conforming to stewardship goals. Overall, tariff changes act as a forcing function that accelerates coordination across clinical, supply chain, regulatory, and finance functions.

In-depth segmentation analysis revealing how drug class, administration route, end user, distribution channel, and clinical application collectively determine procurement and clinical strategies

Understanding the market requires a granular view by drug class, route of administration, end user, distribution channel, and application. The drug class landscape spans antibiotics, antifungals, antiseptics, and antivirals; within antibiotics there are subclasses including carbapenems, cephalosporins, fluoroquinolones, macrolides, and penicillins, while antifungals encompass azoles, echinocandins, and polyenes, antiseptics include alcohol-based preparations, chlorhexidine, and iodophors, and antivirals cover therapies for hepatitis B, hepatitis C, HIV, and influenza. Each of these categories presents distinct clinical usage patterns, stewardship considerations, manufacturing requirements, and regulatory pathways, which together influence procurement priorities and hospital formularies.

Routes of administration are a critical determinant of clinical deployment and supply complexities, with inhalation, oral, parenteral, and topical modalities shaping both clinical pathways and logistics; parenteral delivery in particular breaks down into intramuscular, intravenous, and subcutaneous forms that require specialized sterile manufacturing, cold chain considerations, and nursing competencies for administration. End users such as ambulatory surgery centers, clinics, home healthcare settings, and hospitals differ in purchasing power, storage infrastructure, and treatment protocols, necessitating tailored distribution approaches and patient education strategies. Distribution channels also vary between hospital pharmacy, online pharmacy, retail pharmacy, and wholesalers, each carrying distinct lead times, contractual norms, and compliance obligations.

Application segments-palliative, prophylaxis, and treatment-drive therapeutic selection and inventory planning. Prophylaxis itself subdivides into post-operative and pre-operative use cases that align with scheduling and surgical services, while treatment divides into empirical and targeted therapy, which requires different diagnostic and stewardship support. Integrating these segmentation layers enables stakeholders to better align clinical pathways with supply chain design, ensuring that the right formulation, route, and distribution channel are matched to the appropriate end user and application.

Regional strategic analysis describing how Americas, Europe Middle East & Africa, and Asia-Pacific differences shape regulatory, manufacturing, and distribution priorities for hospitals

Regional dynamics exert a strong influence on therapeutic availability, regulatory expectations, and commercial strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, consolidation among hospital systems and an emphasis on value-based procurement drive demand for therapies that demonstrate clear clinical and economic benefits, while distribution networks are often oriented toward centralized group purchasing and integrated supply agreements. By contrast, Europe, Middle East & Africa present heterogenous regulatory environments and procurement frameworks where national regulations, reimbursement mechanisms, and regional manufacturing hubs shape access and pricing. Policy initiatives stressing antimicrobial stewardship and infection prevention can also vary significantly across jurisdictions.

Asia-Pacific offers diverse dynamics with rapidly expanding healthcare capacity in some markets and advanced manufacturing capabilities in others. Several countries in the region prioritize local production and export-oriented pharmaceutical industries, affecting global supply chains for active pharmaceutical ingredients and sterile components. These geographic differences require manufacturers and distributors to adopt differentiated go-to-market approaches, invest in regulatory intelligence, and develop localized supply chain redundancies. Overall, regional strategy must account for regulatory timelines, procurement customs, manufacturing concentration, and clinical practice variation to ensure both availability and appropriate clinical use.

Insightful corporate analysis of how innovators, specialists, generics, and distribution partners shape access, resilience, and clinical support in hospital infection therapeutics

The competitive landscape spans multinational pharmaceutical innovators, specialist biotech companies focused on novel antimicrobials and antivirals, generics manufacturers, and distributors that facilitate hospital access. Industry leaders with broad infectious disease portfolios often combine antiviral and antibacterial R&D with large-scale manufacturing and established distribution networks, enabling rapid deployment of new therapies when clinically validated. Specialist biotech firms and academic spinouts are frequently the source of next-generation agents and adjunctive therapies, while generics and contract manufacturers play a vital role in maintaining cost-effective access and production resilience.

Distribution and pharmacy service providers increasingly differentiate through value-added services such as clinical support tools, stewardship analytics, and managed inventory solutions. This trend has elevated the importance of partnerships between manufacturers and distributors to ensure that stewardship objectives and formulary decisions are supported by timely supply and clinician education. Additionally, companies investing in sterile manufacturing capacity and quality systems are better positioned to serve the hospital parenteral market, where regulatory scrutiny and the need for validated production present high barriers to entry. Insight into these corporate strategies helps stakeholders evaluate partner selection, potential acquisition targets, and collaboration opportunities to strengthen supply continuity and clinical outcomes.

Practical and prioritized recommendations for clinical, procurement, manufacturing, and commercial leaders to reinforce supply resilience, stewardship, and market agility

Industry leaders should prioritize cross-functional governance that brings together clinical, procurement, regulatory, and commercial teams to align on formulary decisions, contract structures, and contingency planning. Strengthening supplier qualification processes and diversifying sources for active pharmaceutical ingredients and sterile components reduces exposure to geographic and policy disruptions. At the same time, investing in diagnostic enablement and stewardship analytics helps shift utilization toward targeted therapy, preserving clinical efficacy and slowing resistance trends.

Commercial and distribution strategies must adapt to evolving procurement behaviors by offering flexible contracting models, accredited supply assurances, and educational support for clinical adoption. Manufacturers with capabilities in sterile manufacturing and robust quality systems should consider capacity signaling and strategic partnerships to support hospital needs. Additionally, building scenario planning into strategic reviews will help organizations respond to tariff changes, regulatory shifts, and sudden demand spikes by clearly defining trigger points for inventory adjustments, alternative sourcing, or therapeutic substitution. Collectively, these steps enhance preparedness while aligning commercial incentives with clinical quality objectives.

Transparent research methodology detailing primary engagements, supply chain mapping, qualitative validation, and scenario analysis used to develop the executive insights

The research approach combined primary engagement with clinical leaders, procurement professionals, and industry executives alongside secondary analysis of regulatory filings, quality guidance, and open-source industry reporting. Qualitative interviews provided context on operational constraints and adoption barriers, while supply chain mapping identified critical nodes for active pharmaceutical ingredient sourcing, sterile componentry, and distribution flows. The analytical framework integrated clinical pathway mapping with supplier risk assessment and commercial channel evaluation to generate holistic insights.

Validation was achieved through triangulation across interview feedback, manufacturer disclosures, and publicly available regulatory action summaries. Scenario analysis was applied to assess resilience under supply disruption and policy shifts, with particular attention to parenteral manufacturing constraints and distribution channel flexibility. Emphasis was placed on transparent assumptions and the reproducibility of method steps so that stakeholders can adapt the approach to their internal decision-making and perform targeted due diligence where necessary.

Conclusive synthesis of strategic priorities emphasizing clinical stewardship, supply diversification, and cross-functional execution to protect patient care and access

Hospital infection therapeutics sit at the intersection of clinical urgency and operational complexity. Ensuring patient safety and effective therapeutic access requires integrated action across clinical stewardship, procurement policy, manufacturing strategy, and distribution design. Recent changes in trade policy, evolving clinical diagnostics, and shifting distribution models compound the need for cross-functional coordination and contingency planning. Organizations that proactively diversify supply, invest in diagnostic-driven prescribing, and structure flexible commercial agreements will be better positioned to maintain continuity and support optimal clinical outcomes.

Ultimately, success depends on translating insight into operational practice: aligning formularies with stewardship objectives, qualifying multiple supply sources for critical sterile products, and leveraging partnerships that provide both clinical outreach and inventory solutions. By taking a strategic, integrated approach, hospitals, manufacturers, and distributors can mitigate near-term disruptions and build the adaptive capabilities necessary to respond to future challenges in infection therapeutics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Hospital Infection Therapeutics Market, by Drug Class

  • 8.1. Antibiotics
    • 8.1.1. Carbapenems
    • 8.1.2. Cephalosporins
    • 8.1.3. Fluoroquinolones
    • 8.1.4. Macrolides
    • 8.1.5. Penicillins
  • 8.2. Antifungals
    • 8.2.1. Azoles
    • 8.2.2. Echinocandins
    • 8.2.3. Polyenes
  • 8.3. Antiseptics
    • 8.3.1. Alcohol Based
    • 8.3.2. Chlorhexidine
    • 8.3.3. Iodophors
  • 8.4. Antivirals
    • 8.4.1. Anti-HBV
    • 8.4.2. Anti-HCV
    • 8.4.3. Anti-HIV
    • 8.4.4. Anti-Influenza

9. Hospital Infection Therapeutics Market, by Route Of Administration

  • 9.1. Inhalation
  • 9.2. Oral
  • 9.3. Parenteral
    • 9.3.1. Intramuscular
    • 9.3.2. Intravenous
    • 9.3.3. Subcutaneous
  • 9.4. Topical

10. Hospital Infection Therapeutics Market, by Application

  • 10.1. Palliative
  • 10.2. Prophylaxis
    • 10.2.1. Post-Operative
    • 10.2.2. Pre-Operative
  • 10.3. Treatment
    • 10.3.1. Empirical
    • 10.3.2. Targeted Therapy

11. Hospital Infection Therapeutics Market, by End User

  • 11.1. Ambulatory Surgery Centers
  • 11.2. Clinics
  • 11.3. Home Healthcare
  • 11.4. Hospitals

12. Hospital Infection Therapeutics Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy
  • 12.4. Wholesalers

13. Hospital Infection Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Hospital Infection Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Hospital Infection Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Hospital Infection Therapeutics Market

17. China Hospital Infection Therapeutics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. AstraZeneca plc
  • 18.7. Aurobindo Pharma Ltd.
  • 18.8. Basilea Pharmaceutica Ltd.
  • 18.9. Bayer AG
  • 18.10. Bristol-Myers Squibb Company
  • 18.11. Cipla Limited
  • 18.12. F. Hoffmann-La Roche Ltd
  • 18.13. Gilead Sciences, Inc.
  • 18.14. GlaxoSmithKline plc
  • 18.15. Iterum Therapeutics plc
  • 18.16. Johnson & Johnson Services, Inc.
  • 18.17. Melinta Therapeutics, LLC
  • 18.18. Merck & Co., Inc.
  • 18.19. Pfizer Inc.
  • 18.20. Sanofi S.A.
  • 18.21. Shionogi & Co., Ltd.
  • 18.22. Spero Therapeutics, Inc.
  • 18.23. Teva Pharmaceutical Industries Ltd.
  • 18.24. Theravance Biopharma, Inc.
  • 18.25. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CARBAPENEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CARBAPENEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CARBAPENEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CEPHALOSPORINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CEPHALOSPORINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY FLUOROQUINOLONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY FLUOROQUINOLONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PENICILLINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PENICILLINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PENICILLINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY AZOLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY AZOLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY AZOLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ECHINOCANDINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ECHINOCANDINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ECHINOCANDINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY POLYENES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY POLYENES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY POLYENES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTISEPTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTISEPTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTISEPTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTISEPTICS, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ALCOHOL BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ALCOHOL BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ALCOHOL BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CHLORHEXIDINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CHLORHEXIDINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CHLORHEXIDINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY IODOPHORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY IODOPHORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY IODOPHORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-HBV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-HBV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-HBV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-HCV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-HCV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-HCV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-HIV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-HIV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-HIV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-INFLUENZA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-INFLUENZA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-INFLUENZA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PALLIATIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PALLIATIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PALLIATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY POST-OPERATIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY POST-OPERATIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY POST-OPERATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PRE-OPERATIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PRE-OPERATIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PRE-OPERATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY EMPIRICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY EMPIRICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY EMPIRICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY WHOLESALERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY WHOLESALERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY WHOLESALERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTISEPTICS, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTISEPTICS, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTISEPTICS, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTISEPTICS, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTISEPTICS, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTISEPTICS, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTISEPTICS, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTISEPTICS, 2018-2032 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 242. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTISEPTICS, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 252. ASEAN HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 253. ASEAN HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 254. ASEAN HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 256. GCC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 257. GCC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 258. GCC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 259. GCC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 260. GCC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTISEPTICS, 2018-2032 (USD MILLION)
  • TABLE 261. GCC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 262. GCC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 263. GCC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 264. GCC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 265. GCC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 266. GCC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 267. GCC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 268. GCC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTISEPTICS, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPEAN UNION HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPEAN UNION HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPEAN UNION HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPEAN UNION HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 286. BRICS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTISEPTICS, 2018-2032 (USD MILLION)
  • TABLE 287. BRICS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 288. BRICS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 289. BRICS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 290. BRICS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 291. BRICS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 292. BRICS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 293. BRICS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 294. BRICS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 295. G7 HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 296. G7 HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 297. G7 HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 298. G7 HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 299. G7 HOSPI